Use this URL to cite or link to this record in EThOS: http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.690225
Title: How point mutations confer resistance in BCR-ABL : a computational study
Author: Clapton, Genevieve
ISNI:       0000 0004 5922 4295
Awarding Body: University of Southampton
Current Institution: University of Southampton
Date of Award: 2015
Availability of Full Text:
Access from EThOS:
Full text unavailable from EThOS. Please try the link below.
Access from Institution:
Abstract:
Imatinib is a first generation BCR-Abl tyrosine kinase inhibitor widely used in the treatment of CML. A significant cause of relapse in patients receiving imatinib therapy can be attributed to the development of point mutations in the BCR-Abl tyrosine kinase and resulting imatinib-resistance. Nilotinib is one of several second generation BCR-Abl tyrosine kinase inhibitors developed to treat imatinib-resistant CML. Nilotinib inhibits the majority of imatinib-resistant mutations, however mutations that are resistant to both imatinib and nilotinib persist in patients. These highly resistant mutations include compound mutants, where multiple mutations occur in the same BCR-Abl molecule. Further understanding regarding how mutations confer resistance and the ability to predict the resistance profile of a given compound mutation would enable drug design initiatives, both in CML and other cancers, to be improved in the future. In this thesis three major computational approaches; molecular dynamics, ligand docking and MM-GBSA have been applied to investigate the effects of single and compound point mutations in the BCR-Abl kinase domain. Wild-type structures of BCR-Abl were studied initially in order to validate methods and act as a benchmark for comparison against the mutant structures. A total of ten mutant structures of inactive BCR-Abl were studied; five in complex with imatinib and five with nilotinib. Using this approach we were able to rank the single mutant structures according to experimental data and test the protocol on two previously unstudied compound mutations.
Supervisor: Essex, Jonathan Sponsor: Not available
Qualification Name: Thesis (Ph.D.) Qualification Level: Doctoral
EThOS ID: uk.bl.ethos.690225  DOI: Not available
Share: